A clinical trial found breakthrough results in treating multiple myeloma - a blood cancer considered incurable. The study examined 97 patients whose disease had returned after multiple treatments and who faced a short life expectancy. After an innovative treatment called Carvykti and follow-up of five years or more, one-third of patients remained disease-free. The treatment is based on CAR-T technology, which involves genetic engineering of T cells, the patient's own immune system cells, to train them to identify, attack and destroy myeloma cancer cells in a targeted manner.